Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
DIPHENYLAMINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY
Document Type and Number:
WIPO Patent Application WO/2019/120121
Kind Code:
A1
Abstract:
Disclosed are a diphenylaminopyrimidine compound having an inhibitory effect on protein tyrosine kinase, pharmaceutically acceptable salts, crystal forms, prodrugs, metabolites, hydrates, solvates, stereoisomers or isotope derivatives thereof, a pharmaceutical composition comprising these compounds, as well as preparation and use of these compounds. The compound has a structure as represented by formula (I), and can be used for treating ALK-mediated cancer-related symptoms, such as non-small cell lung cancer, breast cancer, nerve tumors, esophagus cancer, soft tissue cancer, lymphoma, or leukemia.

Inventors:
WANG YIHAN (CN)
LI HUANYIN (CN)
Application Number:
PCT/CN2018/120618
Publication Date:
June 27, 2019
Filing Date:
December 12, 2018
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
SHENZHEN TARGETRX INC (CN)
International Classes:
C07D239/48; A61K31/505; A61P35/00; C07D401/12
Domestic Patent References:
WO2013169401A12013-11-14
Foreign References:
CN103501612A2014-01-08
CN103153064A2013-06-12
CN102105150A2011-06-22
CN106336382A2017-01-18
CN105330698A2016-02-17
US9611283B12017-04-04
US5376645A1994-12-27
US7091213B22006-08-15
Other References:
BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
T. HIGUCHIV. STELLA: "Bioreversible Carriers in Drug Design", vol. 14, 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS, article "Prodrugs as Novel Delivery Systems, A.C.S. Symposium Series"
D. FLEISHERS. RAMONH. BARBRA: "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", ADVANCED DRUG DELIVERY REVIEWS, vol. 19, no. 2, 1996, pages 115 - 130
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY
See also references of EP 3715343A4
Download PDF: